期刊文献+

挤出-滚圆法制备吗替麦考酚酯微丸 被引量:2

Preparation of Mycophenolate Mofetil Pellets by Extrusion-spheronization Process
原文传递
导出
摘要 采用挤出-滚圆法制备吗替麦考酚酯微丸,以单因素试验优化了挤出-滚圆工艺参数及黏合剂、崩解剂和微晶纤维素用量等处方因素。所得优化工艺为:吗替麦考酚酯75%,微晶纤维素15%,崩解剂羧甲淀粉钠10%,并以含1.5%羧甲纤维素钠的25%乙醇为黏合剂,挤出和滚圆速度为928 r/min,滚圆5 min。制品表面光滑,坚硬,圆整度良好,能用于后续的流化床包衣,并且在含0.5%十二烷基磺酸钠的p H 6.8磷酸钠缓冲液中2 h累积释放率达80%以上。 The mycophenolate mofetil(1) pellets were prepared by extrusion-spheronization method. The process parameters of extrusion-spheronization and formulation factors such as the amounts of adhesive, disintegrant and microcrystalline cellulose were optimized by single factor test. The optimal formulation contained 75% of 1, 15%of microcrystalline cellulose, 10% of carboxymethylstarch sodium as disintegrant with 25% ethanol containing 1.5% of carmellose sodium as adhesive. The rates of extrusion and spheronization were 928 r/min, the time of spheronization was 5 min. The pellets prepared under above conditions were smooth, hard and round enough to be coated in the following step. Furthermore, in p H 6.8 sodium phosphate buffer containing 0.5% sodium dodecyl sulfonate, the cumulative release at 2 h of the optimal pellets was above 80%.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第12期1155-1159,共5页 Chinese Journal of Pharmaceuticals
关键词 挤出-滚圆法 吗替麦考酚酯 微丸 extrusion-spheronization mycophenolate mofetil pellet
  • 相关文献

参考文献6

  • 1陈頔,刘蕾,彭丹涛,孙春华,许贤豪.吗替麦考酚酯在自身免疫疾病中的临床应用[J].中国神经免疫学和神经病学杂志,2009,16(2):144-147. 被引量:5
  • 2Shaw LM,Holt DW,Oellerich M,et al.Current issues in therapeutic drug monitoring of mycophenolic acid:report of a roundtable discussion[J].Ther Drug Monit,2001,23 (4):305-315.
  • 3Cox VC,Ensom MH.Mycophenolate mofetil for solid organ transplantation:does the evidence support the need for clinical pharmacokinetic monitoring?[J].Ther Drug Monit,2003,25(2):137-157.
  • 4梁超峰,欧阳允,陈平,骆慧红,罗国威.润湿粘合剂对小丸制备的影响[J].中国医药工业杂志,2000,31(4):159-161. 被引量:5
  • 5Podczeck F,Knight PE,Newton JM.The evaluation of modified microcrystalline cellulose for the preparation of pellets with high drug loading by extrusion/spheronization[J].Int J Pharm,2008,350 (1-2):145-154.
  • 6陈婷,张倩,宋洪涛.口服缓控释微丸的研究进展[J].药学实践杂志,2011,29(3):169-172. 被引量:10

二级参考文献48

  • 1陆福明 ,丁小强 ,陈楠 ,钱家麒 ,徐琴君 ,袁伟杰 ,梅长林 ,徐玉兰 ,侯凡凡 ,林善锬 .吗替麦考酚酯治疗原发性肾病综合征的前瞻性多中心临床研究[J].中华肾脏病杂志,2004,20(4):238-241. 被引量:35
  • 2秦炯.重症肌无力的免疫发病机制及相关治疗进展[J].临床儿科杂志,2007,25(2):85-87. 被引量:14
  • 3刘晓渭,许国双,王汉民,刘宏宝,白淑蓉,孙世仁,陈威,张鹏.霉酚酸酯与环磷酰胺治疗重症IgA肾病的疗效比较[J].西南国防医药,2007,17(3):289-291. 被引量:6
  • 4贺芬.控释小药丸的制备[J].国外药学-合成药、生化药、制剂分册,1987,8(1):31-34.
  • 5郑颉.设计口服控释小丸剂应考虑的几项问题[J].中国医药工业杂志,1989,20(2):89-93.
  • 6Allison AC, Eugui EM. Mycophenolate acid and brequinar,inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion moleeules[J]. Immunopharmacology, 2000, 47(2-3): 85-118.
  • 7Meriggioli MN,Ciafaloni E,AI Hayk KA,etal. Mycophenolate mofetil for myasthenia gravis An analysis of efficacy, safety and tolerability[J].Neurology, 2003, 61(10); 1438-1440.
  • 8Schneider C,Gold R, Reiners K,et al. Mycophenolate mofetil in the therapy of severe myasthenia gravis[J]. Eur Neurol,2001,46(2) :79-82.
  • 9Ciafaloni E, Massey JM, Tucker-Lipscomla B, et al. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study[J].Neurology, 2000,56 (1) : 97 -99.
  • 10Schneider C, Gold R, Reiners K, et al. Mycophenolate Mofetil in the Therapy of Severe Myasthenia gravis[J]. Eur neurol, 2001, 46(2): 79-82.

共引文献17

同被引文献15

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部